TWI768467B - 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物 - Google Patents

用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物 Download PDF

Info

Publication number
TWI768467B
TWI768467B TW109131169A TW109131169A TWI768467B TW I768467 B TWI768467 B TW I768467B TW 109131169 A TW109131169 A TW 109131169A TW 109131169 A TW109131169 A TW 109131169A TW I768467 B TWI768467 B TW I768467B
Authority
TW
Taiwan
Prior art keywords
methyl
compound
purin
amino
chlorophenyl
Prior art date
Application number
TW109131169A
Other languages
English (en)
Chinese (zh)
Other versions
TW202108584A (zh
Inventor
梁春根
苗昆
王劍平
貟紅英
鄭秀芳
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI768467(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202108584A publication Critical patent/TW202108584A/zh
Application granted granted Critical
Publication of TWI768467B publication Critical patent/TWI768467B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109131169A 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物 TWI768467B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2015/078507 2015-05-08
CN2015078507 2015-05-08
WOPCT/CN2016/078785 2016-04-08
CN2016078785 2016-04-08

Publications (2)

Publication Number Publication Date
TW202108584A TW202108584A (zh) 2021-03-01
TWI768467B true TWI768467B (zh) 2022-06-21

Family

ID=55910966

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109131169A TWI768467B (zh) 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物
TW105114192A TWI706954B (zh) 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105114192A TWI706954B (zh) 2015-05-08 2016-05-06 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物

Country Status (32)

Country Link
US (3) US9708325B2 (enExample)
EP (1) EP3294740B1 (enExample)
JP (1) JP6738352B2 (enExample)
KR (1) KR102690131B1 (enExample)
CN (1) CN107580596B (enExample)
AR (1) AR104528A1 (enExample)
AU (3) AU2016260683B2 (enExample)
BR (1) BR112017023959B1 (enExample)
CA (1) CA2982704C (enExample)
CL (1) CL2017002745A1 (enExample)
CO (1) CO2017009994A2 (enExample)
CR (1) CR20170496A (enExample)
DK (1) DK3294740T3 (enExample)
ES (1) ES2753777T3 (enExample)
HR (1) HRP20191942T1 (enExample)
HU (1) HUE045906T2 (enExample)
IL (2) IL254947B (enExample)
LT (1) LT3294740T (enExample)
MX (2) MX376761B (enExample)
MY (1) MY182353A (enExample)
NZ (2) NZ735648A (enExample)
PE (1) PE20171620A1 (enExample)
PH (1) PH12017502009A1 (enExample)
PL (1) PL3294740T3 (enExample)
PT (1) PT3294740T (enExample)
RS (1) RS59435B1 (enExample)
RU (1) RU2745269C2 (enExample)
SG (1) SG10202108841YA (enExample)
SI (1) SI3294740T1 (enExample)
TW (2) TWI768467B (enExample)
UA (1) UA120450C2 (enExample)
WO (1) WO2016180695A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ735648A (en) 2015-05-08 2023-06-30 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
SG11201901633WA (en) 2016-08-29 2019-03-28 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
WO2018050571A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
CA3091950A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CN114450280B (zh) 2019-09-20 2025-02-25 先正达农作物保护股份公司 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132590A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
WO2024013205A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193282A (ja) * 1997-12-26 1999-07-21 Sumitomo Pharmaceut Co Ltd 複素環化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540396A (ja) * 2005-05-04 2008-11-20 ファイザー・リミテッド 癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
PL2978429T3 (pl) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Deazapurynony makrocykliczne do leczenia infekcji wirusowych
BR112017002811B1 (pt) 2014-08-15 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
NZ735648A (en) * 2015-05-08 2023-06-30 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
SG11201901633WA (en) * 2016-08-29 2019-03-28 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193282A (ja) * 1997-12-26 1999-07-21 Sumitomo Pharmaceut Co Ltd 複素環化合物

Also Published As

Publication number Publication date
US9708325B2 (en) 2017-07-18
TW201716410A (zh) 2017-05-16
SI3294740T1 (sl) 2019-12-31
BR112017023959A2 (pt) 2018-07-17
AU2016260683A1 (en) 2017-10-12
PE20171620A1 (es) 2017-11-02
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
SG10202108841YA (en) 2021-09-29
PT3294740T (pt) 2019-10-29
HUE045906T2 (hu) 2020-01-28
ES2753777T3 (es) 2020-04-14
AR104528A1 (es) 2017-07-26
RS59435B1 (sr) 2019-11-29
MY182353A (en) 2021-01-20
BR112017023959B1 (pt) 2023-05-02
NZ735648A (en) 2023-06-30
MX393198B (es) 2025-03-19
TWI706954B (zh) 2020-10-11
CN107580596B (zh) 2020-07-14
MX2020010949A (es) 2022-06-16
IL280769B1 (en) 2023-03-01
US20170275286A1 (en) 2017-09-28
EP3294740B1 (en) 2019-09-04
IL280769A (en) 2021-04-29
CL2017002745A1 (es) 2018-05-18
CO2017009994A2 (es) 2018-02-20
HK1247925A1 (zh) 2018-10-05
AU2022204666A1 (en) 2022-07-21
LT3294740T (lt) 2019-11-25
US20160326177A1 (en) 2016-11-10
PH12017502009A1 (en) 2018-03-26
CR20170496A (es) 2017-12-05
NZ775222A (en) 2024-09-27
US10399983B2 (en) 2019-09-03
RU2017142577A (ru) 2019-06-10
AU2020256348B2 (en) 2022-06-16
CA2982704A1 (en) 2016-11-17
CN107580596A (zh) 2018-01-12
IL254947A0 (en) 2017-12-31
AU2020256348A1 (en) 2020-11-12
JP2018515509A (ja) 2018-06-14
DK3294740T3 (da) 2019-11-04
WO2016180695A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
UA120450C2 (uk) 2019-12-10
EP3294740A1 (en) 2018-03-21
CA2982704C (en) 2023-10-24
KR20180003612A (ko) 2018-01-09
US11242345B2 (en) 2022-02-08
US20200109144A1 (en) 2020-04-09
IL280769B2 (en) 2023-07-01
PL3294740T3 (pl) 2020-03-31
MX2017014033A (es) 2018-03-01
MX376761B (es) 2025-03-07
IL254947B (en) 2021-02-28
AU2016260683B2 (en) 2020-10-29
KR102690131B1 (ko) 2024-07-31
JP6738352B2 (ja) 2020-08-12
RU2017142577A3 (enExample) 2019-10-31

Similar Documents

Publication Publication Date Title
TWI768467B (zh) 用於治療及預防病毒感染之新穎磺醯亞胺醯基嘌呤酮化合物及衍生物
JP7654643B2 (ja) ホスホジエステラーゼ阻害剤および使用
JP6936848B2 (ja) 感染症の治療のための新規テトラヒドロピラゾロピリジン化合物
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
EP1761268A2 (en) Pyrrolotriazine kinase inhibitors
JP2025532670A (ja) Pcsk9阻害剤及びその使用方法
JP2022169721A (ja) Irak4阻害剤およびその使用
CN113773335A (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
CN116867782A (zh) 吡唑酰胺衍生物
HK1247925B (zh) 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
CN107406452B (zh) 吡唑并[3,4-d]嘧啶衍生物及其治疗利什曼病的用途
TW202206421A (zh) 作為運鐵素(ferroportin)抑制劑之環烷基嘧啶
TW202513561A (zh) 治療發炎性疾病之方法
HK40076947A (en) Phosphodiesterase inhibitors and use